AB Science Past Earnings Performance
Past criteria checks 0/6
AB Science has been growing earnings at an average annual rate of 14.8%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 10% per year.
Key information
14.8%
Earnings growth rate
21.4%
EPS growth rate
Pharmaceuticals Industry Growth | 14.1% |
Revenue growth rate | -10.0% |
Return on equity | n/a |
Net Margin | -2,173.1% |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How AB Science makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 1 | -17 | 3 | 12 |
31 Mar 23 | 1 | -15 | 3 | 13 |
31 Dec 22 | 1 | -14 | 4 | 13 |
30 Sep 22 | 1 | -15 | 4 | 14 |
30 Jun 22 | 1 | -17 | 4 | 14 |
31 Mar 22 | 2 | -16 | 4 | 13 |
31 Dec 21 | 2 | -14 | 4 | 11 |
30 Sep 21 | 2 | -13 | 4 | 12 |
30 Jun 21 | 2 | -11 | 3 | 12 |
31 Mar 21 | 2 | -13 | 3 | 12 |
31 Dec 20 | 2 | -15 | 3 | 13 |
30 Sep 20 | 2 | -16 | 3 | 12 |
30 Jun 20 | 2 | -18 | 3 | 12 |
31 Mar 20 | 2 | -20 | 3 | 14 |
31 Dec 19 | 2 | -22 | 3 | 16 |
30 Sep 19 | 2 | -25 | 3 | 19 |
30 Jun 19 | 2 | -28 | 3 | 23 |
31 Mar 19 | 2 | -27 | 3 | 25 |
31 Dec 18 | 2 | -26 | 3 | 27 |
30 Sep 18 | 2 | -25 | 3 | 27 |
30 Jun 18 | 2 | -25 | 3 | 27 |
31 Mar 18 | 2 | -26 | 3 | 27 |
31 Dec 17 | 2 | -27 | 3 | 27 |
30 Sep 17 | 2 | -27 | 3 | 26 |
30 Jun 17 | 2 | -26 | 3 | 26 |
31 Mar 17 | 2 | -27 | 3 | 27 |
31 Dec 16 | 2 | -28 | 3 | 28 |
30 Sep 16 | 2 | -28 | 4 | 27 |
30 Jun 16 | 2 | -28 | 4 | 27 |
31 Mar 16 | 2 | -28 | 4 | 25 |
31 Dec 15 | 2 | -27 | 4 | 24 |
30 Sep 15 | 2 | -24 | 4 | 21 |
30 Jun 15 | 2 | -22 | 4 | 19 |
31 Mar 15 | 2 | -19 | 4 | 16 |
31 Dec 14 | 2 | -16 | 4 | 13 |
30 Sep 14 | 2 | -16 | 4 | 13 |
30 Jun 14 | 2 | -15 | 3 | 13 |
31 Mar 14 | 2 | -15 | 3 | 12 |
31 Dec 13 | 2 | -15 | 3 | 12 |
30 Sep 13 | 2 | -13 | 3 | 11 |
30 Jun 13 | 2 | -12 | 3 | 10 |
31 Mar 13 | 2 | -11 | 3 | 9 |
31 Dec 12 | 1 | -11 | 3 | 9 |
Quality Earnings: ABP is currently unprofitable.
Growing Profit Margin: ABP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ABP is unprofitable, but has reduced losses over the past 5 years at a rate of 14.8% per year.
Accelerating Growth: Unable to compare ABP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-41.9%).
Return on Equity
High ROE: ABP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.